$153.38+45.32% · 3M
Moving avg
1W+5.15%
1M+13.23%
3M+50.11%
6M+88.22%
YTD+75.94%
1Y+178.93%
3Y+705.16%
5Y+220.55%
52-week range
$50.49100% of range$143.29
Company health
Value0/6
Growth2/6
Profitability2/6
Health5/6
Dividend0/6
Bull vs bear
Strengths
- Analyst consensus is "Buy"
- Revenue compounding 11% a year
- Net cash on the balance sheet
Risks
- Trades 12% above the average analyst target
- Currently unprofitable
- More volatile than the market (beta 1.8)
Key statistics
Valuation
Market cap
$9.86B
Enterprise value
$8.53B
P/E ratio (TTM)
-75.16x
P/S ratio (TTM)
117.60x
EV/EBITDA
-74.84x
Per share & returns
EPS (TTM)
-$1.76
Dividend yield
0.00%
Beta (1Y)
1.79
30-day change
+13.23%
Trading
Volume (24h)
106.17K
Previous close
$152.01
Shares outstanding
64.31M
About Protagonist Therapeutics, Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
PTGX
Protagonist Therapeutics, Inc. is a mid-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United States) and trade under the ticker PTGX.
Frequently asked questions
What is Protagonist Therapeutics, Inc.'s market cap?
Protagonist Therapeutics, Inc. (PTGX) has a market capitalization of $9.86B.
What sector is Protagonist Therapeutics, Inc. in?
Protagonist Therapeutics, Inc. operates in the Healthcare sector, Biotechnology industry.
What exchange does PTGX trade on?
PTGX trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,215.75-0.37%
$1.14T cap
Johnson & JohnsonJNJ
$261.27+0.16%
$629.63B cap
AbbVie Inc.ABBV
$250.22+0.59%
$442.09B cap
UnitedHealth Group IncorporatedUNH
$402.23-0.83%
$365.28B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$354.73B cap
Merck & Co., Inc.MRK
$134.76+1.38%
$332.83B cap
Novartis AGSWX: NOVN
CHF 123.74-0.37%
$289.30B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.01B cap